Mivacron (Mivacurium)

Mivacurium, the active ingredient in Mivacron, is a non-depolarizing neuromuscular blocking agent presented as an injectable solution for intravenous use. It produces skeletal muscle relaxation by competitively antagonizing acetylcholine at nicotinic receptors, facilitating endotracheal intubation and providing controlled muscle relaxation during surgical procedures.

GNH USA supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures timely delivery, regulatory compliance, and product integrity across multiple regions. We maintain stringent quality controls and provide technical support to healthcare providers.

Mivacurium is a non-depolarizing neuromuscular blocking agent used to facilitate muscle relaxation during anesthesia. - Endotracheal intubation: provides rapid and reliable skeletal muscle relaxation, facilitating safe placement of the airway tube and improving ventilation control during induction. - Surgical procedures: maintains consistent muscle relaxation throughout operative interventions, allowing surgeons optimal exposure and reducing the risk of intra‑operative movement. - Adjunct to general anesthesia: enhances overall anesthetic depth by preventing spontaneous muscle activity, thereby supporting stable hemodynamics and reducing the need for additional sedatives.

Mivacurium may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Transient hypotension: mild drop in blood pressure occurring shortly after injection. - Flushing: redness of the skin, especially on the face and neck. - Bronchospasm: narrowing of the airways causing wheezing, more common in susceptible individuals. - Histamine release: mild itching or rash due to release of histamine. - Nausea: sensation of queasiness that may precede vomiting. - Vomiting: expulsion of stomach contents, may occur after injection.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction that can be life‑threatening. - Prolonged neuromuscular blockade: extended muscle paralysis requiring extended ventilation support. - Cardiac arrhythmias: irregular heart rhythms that may need medical intervention. - Respiratory depression: reduced breathing effort that may require assisted ventilation.

When using Mivacurium, clinicians should observe several precautions to ensure patient safety and optimal drug performance. - Dose titration: adjust dosage based on neuromuscular monitoring and patient response. - Allergy history: assess for hypersensitivity to mivacurium or related compounds before administration. - Renal or hepatic impairment: use with caution and monitor duration of action, as clearance may be altered. - Concurrent neuromuscular blockers: avoid additive effects that could prolong paralysis. - Pregnancy and lactation: consider only if potential benefit justifies potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacurium can interact with other medications, influencing its neuromuscular blocking effect.

Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin, streptomycin): potentiate the neuromuscular blockade of mivacurium, increasing the risk of prolonged paralysis and respiratory failure. - Magnesium sulfate: synergistically enhances mivacurium’s effect on the neuromuscular junction, potentially leading to severe respiratory depression and the need for extended ventilation.

Moderate Interactions (Monitor Closely): - Volatile anesthetics (e.g., sevoflurane, isoflurane): may augment the muscle‑relaxing action of mivacurium, so clinicians should monitor depth of blockade and adjust the dose accordingly. - Lithium therapy: can lengthen the duration of mivacurium‑induced paralysis, necessitating careful neuromuscular monitoring. - Calcium channel blockers (e.g., verapamil, diltiazem): may interfere with calcium‑dependent processes at the neuromuscular junction, potentially modifying the response to mivacurium.